Laval, QC — December 1, 2025 — Bausch Health’s aesthetics division, Solta Medical, has completed the acquisition of Wuhan Shibo Zhenmei Technology Co., Ltd., its longtime distribution partner in China. The transaction transitions Shibo into a wholly owned subsidiary of Solta Medical, giving the company full control of distribution for premium aesthetic technologies such as Thermage® FLX across one of the fastest-growing aesthetics markets in the world. The move strengthens Solta Medical’s market penetration, expands direct access to customers, and reinforces the company’s long-term commitment to delivering high-quality aesthetic solutions for providers and patients throughout China.
Science Significance
Although the acquisition is a business transaction, its scientific relevance lies in enhancing the deployment of regulated aesthetic medical devices that rely on precise engineering, validated energy-delivery mechanisms, and rigorous quality controls. Solta Medical’s platforms—such as Thermage® FLX—are built on radiofrequency-based technology that requires consistent calibration, compliant servicing, and robust distribution oversight to maintain treatment reliability. By integrating Shibo’s experienced team directly into Solta’s operations, the company strengthens its ability to ensure scientific integrity, device consistency, and post-market performance through more tightly controlled logistics and technical support. This creates a better environment for quality-assured device operation across clinical aesthetic settings in China.
Regulatory Significance
The acquisition provides Solta Medical with greater control over compliance pathways in a region where medical-device regulations are evolving rapidly. As China continues to tighten oversight of aesthetic and energy-based devices, direct ownership of distribution enables Solta Medical to more effectively align with Chinese regulatory requirements, including device registration, import controls, quality documentation, and after-sales service obligations. By moving away from a third-party distribution model, Solta Medical can ensure more consistent adherence to Good Distribution Practices (GDP) and local device-compliance frameworks while maintaining traceability across the product lifecycle. This strengthens regulatory readiness and supports long-term market stability for Solta’s globally recognized aesthetic technologies.
Business Significance
Advertisement
For Bausch Health, the acquisition represents a strategic acceleration of its global aesthetics growth plan. CEO Thomas J. Appio emphasized that the transaction immediately expands Solta Medical’s market scale and customer reach in China. By leveraging Shibo’s established network and deep local insights developed over a decade-long partnership, Solta Medical gains direct access to a broad customer base capable of driving future revenue and market-share growth. Leadership from both companies noted that integrating Shibo’s team allows Solta Medical to move faster, react swiftly to market changes, and provide enhanced service to aesthetic-care providers. The deal positions Solta Medical as an even stronger growth engine within Bausch Health’s diversified global portfolio, reinforcing its standing in the rapidly expanding Asian aesthetics sector.
Patients’ Significance
For patients seeking advanced aesthetic treatments, the acquisition enhances Solta Medical’s ability to deliver high-quality, reliable, and trusted technologies within China. By directly managing distribution, Solta Medical can streamline device availability, improve service responsiveness, and ensure that technologies like Thermage® FLX maintain consistent performance across clinics. Jiny Kim, Senior Vice President of Solta Medical, highlighted that closer proximity to customers supports faster innovation and stronger feedback loops, ultimately improving treatment outcomes and patient satisfaction. With rising demand for non-invasive aesthetic therapies, the enhanced presence in China increases access to safe, effective, and technologically robust aesthetic devices, aligning patient expectations with international standards.
Policy Significance
The acquisition reflects broader health-policy trends in China, where regulators are emphasizing quality assurance, device-traceability, and ethical practice in the medical-aesthetics sector. Owning its distribution channel allows Solta Medical to contribute more effectively to policy-driven quality initiatives, including proper device servicing, responsible marketing practices, and compliance with evolving national standards for medical beauty products. As China continues to formalize oversight of the booming aesthetics market, Solta Medical’s integrated model supports alignment with regional policy goals, promotes transparency in device supply chains, and helps ensure that aesthetic-care providers deliver treatments using verified, regulatory-compliant technologies. This strengthens trust among consumers, regulators, and healthcare stakeholders.
Solta Medical’s acquisition of the Shibo Group marks a pivotal advancement in its strategy to deepen its presence in China’s rapidly expanding aesthetics market. By bringing a decade-long partner fully under Solta’s operational umbrella, the company gains the distribution agility, regulatory alignment, and customer connectivity needed to support sustained growth. As part of Bausch Health’s broader vision to enrich global healthcare outcomes, the strengthened China footprint enhances Solta Medical’s ability to deliver innovative, high-quality aesthetic solutions that benefit providers and patients alike, while reinforcing its leadership in the global aesthetics landscape.
Source: Bausch Health Companies Inc. press release
